Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of entinostat + fulvestrant in HR-positive/HER2-negative advanced breast cancer after endocrine therapy failure
ChiCTR2000035277Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of entinostat and fulvestrant in breast cancer (3 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: Progression-free survival and Rate of adverse events. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
entinostatfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000035277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035277.